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The test of production of the 99Mo/99mTc complex by means of Varian
medical linear accelerators used in teleradiotherapy was performed. The
targets made of the natural molybdenum were irradiated by high-energy
therapeutic 20 MV X-ray beam. 99Mo was produced mainly in the pho-
tonuclear reaction of 110Mo(γ, n)99Mo. The obtained specific activities are
relatively small in the saturation state (from 155.4 kBq/g to 163.2 kBq/g)
because only the high-energetic part of the spectrum of 20 MV X-ray beam
covers the energy range of the 110Mo(γ, n)99Mo reaction cross section. The
new application of the 99Mo/99mTc complex of the low activity was sug-
gested using the molybdenum nanoparticle technology.
DOI:10.5506/APhysPolB.47.777
1. Introduction
Most of the radiopharmaceuticals used nowadays are based on 99mTc.
The main sources of the 99Mo/99mTc complex are nuclear reactors [1]. The
main advantage of using reactors to produce 99Mo/99mTc generators is a
very intense neutron flux. However, in the last decade, several independent
reactor shutdowns and outage extensions significantly disrupted global 99Mo
supplies. These unplanned events, combined with other planned outages cre-
ated a worldwide 99Mo supply crisis. Therefore, new methods of production
of technetium are required. The methods based on cyclotrons [2, 3] and
dedicated electron linear accelerators [4, 5] are used more and more often.
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The aim of this work was to test a possibility of 99Mo/99mTc production by
means of the Varian medical linacs used in teleradiotherapy. The targets
made of the natural molybdenum were irradiated by a high-energy thera-
peutic 20 MV X-ray beam. The 99Mo radioisotope can be produced in the
photonuclear reaction: 110Mo(γ, n)99Mo induced by gammas of the thera-
peutic beam. The reactions: 110Mo(n, 2n)99Mo induced by fast neutrons
and 98Mo(n, γ)99Mo were also considered. The neutrons are a contamina-
tion of the therapeutic X rays. They originate from the photonuclear reac-
tions occurring mainly in the massive components of the medical accelerator
head [6–8]. The irradiations were performed at the Maria Skłodowska-Curie
Memorial Cancer Centre and Institute of Oncology in Gliwice (Poland). The
activities of the produced radioisotopes were measured at the Department
of Nuclear Physics and Its Applications of the Institute of Physics of the
University of Silesia in Katowice (Poland).
2. Materials and methods
The molybdenum targets of the 1 cm × 1 cm × 1 mm size were located
on the accelerator window during irradiation. In such location, the molyb-
denum target is irradiated by gammas and neutrons. As the performed
simulations showed, the gamma flux was 1010 cm−2s−1 whereas the neutron
flux was 105 cm−2s−1 in the target for the maximal efficiency of the acceler-
ators. The gamma energy spectra and those of neutrons at the accelerator
window are presented in Fig. 1. The cross sections for the possible reactions
in which the 99Mo radioisotope can be produced are shown in Fig. 2. The
activities of the produced radioisotopes of 99Mo and 99mTc were determined
using the energy spectra of gammas emitted by these radioisotopes. The
spectra were measured by means of the Ge(Li) semiconductor detector. The
efficiency calibration of the detector was performed with the use of the com-
mercial sources of 152Eu and 133Ba. The activity of 99Mo was determined
on the base of the net area of the photopeak at 181.1 keV, whereas that of
99mTc was related to the photopeak at 140.5 keV.
The radioisotope of 99Mo originates mainly from the 110Mo(γ, n)99Mo re-
action because the photon flux at the target is 5 orders of magnitude greater
than the neutron flux. The 110Mo(n, 2n)99Mo reaction is of minor impor-
tance, because at the target only 0.4% of all neutrons have energy greater
than 8 MeV. The contribution of thermal neutrons is also small. The ther-
mal neutrons constitute 27% of all neutrons at the target. However, the
maximum cross section of the 98Mo(n, γ)99Mo reaction is about 6 times
lower than the maximum photonuclear cross section of the 110Mo(γ, n)99Mo
reaction (253 mb). This observation was verified experimentally by the com-
parison of the 99Mo activities induced in the photon and neutron field and
in the neutron field exclusively.
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(a) (b)
Fig. 1. (a) The gamma energy spectrum of the therapeutic 20 MV X-ray beam used
in this work. (b) The energy spectrum of neutrons originating from photonuclear
reactions induced by the mentioned therapeutic X rays. The zoom of the spectrum
in the energy range from 0.1 MeV to 10 MeV is presented in the insert. The spectra
were derived from the Monte Carlo simulations based on the Geant4 code.
Fig. 2. The cross sections of the following reactions: 110Mo(γ, n)99Mo,
110Mo(n, 2n)99Mo and 98Mo(n, γ)99Mo considered as possible ways of production
of 99Mo (from the ENDF data base).
3. Results and discussion
The molybdenum targets were irradiated by means of the therapeutic
20 MV X rays from two Varian linear accelerators: Clinac 2300 and True-
Beam. The irradiation time was between 10 and 20 minutes. The irradia-
tions were carried out under various conditions. The irradiation conditions
differed in a radiation field size and a location of the target in relation to the
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central axis of the beam. The radiation fields determined at SSD = 100 cm
were 3 cm × 3 cm, 10 cm × 10 cm and 40 cm × 40 cm. The irradiations were
performed using the mode with the maximal efficiency of 600 monitor units
(MU) per minute. 1 MU corresponded to 1 cGy of the therapeutic X-ray
dose at the reference depth of 10 cm in water. The exemplary gamma-ray
spectrum for the irradiated molybdenum target is presented in Fig. 3.
Fig. 3. The gamma-ray spectrum for the natural molybdenum target irradiated by
means of the therapeutic 20 MV X-ray beam from the medical linear accelerator
(TrueBeam). The photopeaks from the decays of 99Mo are denoted. Duration of
the spectrum measurement was 260 h (Ge(Li) detector).
The saturation curves were determined for the targets irradiated under
various conditions. The chosen saturation curves determined on the base
of the activities of the produced 99Mo radioisotope are presented in Fig. 4.
Obviously, the activity of 99mTc is equal to the activity of 99Mo in the
saturation state. In general, the differences between the saturation curves
obtained under the various irradiation conditions are small, i.e. the specific
activities in the saturation state differ by less than 3%. The saturated
specific activities fall in the range of 155.4 kBq/g–163.2 kBq/g and their
uncertainties are less than 1%. An attempt to increase the induced activity
was carried out by means of the 5 cm thick slab of lead located behind the
molybdenum target in the X-ray beam: the slab was an additional source
of fast neutrons originating from photonuclear reactions with nuclei of lead.
It made it possible to increase significantly (by 50%) the activity of 99Mo.
The details of this approach will be presented in the subsequent paper.
Test of Production of 99Mo/99mTc by Means of Typical Medical Linear . . . 781
Fig. 4. The saturation curves determined for the produced radioisotope of 99Mo,
for various irradiation conditions.
Though the obtained specific activities are too small for the tested method
to be applied in the large scale production of the 99Mo/99mTc generator,
however, one can consider a novel application of the described method in
the radiotherapy treatment based on a use of nanoparticles. Many studies in-
dicate that the dose enhancement is obtained when the high atomic number
metal nanoparticles are introduced to a target volume [9, 10]. This dose en-
hancement is caused by the increase of the photoelectric effect due to irradia-
tion with the therapeutic megavoltage X rays. The methods for the synthesis
of Mo nanoparticles are already well-known [11–17]. Such nanoparticles are
used in lithium-ion batteries [18], hydrogen evolution catalysis [19], transis-
tors [20], photodetectors [21], sensors and biosensors [22, 23] and memory
devices [24], etc. We suggest a new application of the nanoparticles with the
radioactive molybdenum of 99Mo as an additional dose enhancement tool.
The local dose enhancement is expected to be caused not only by photons
from the disintegration of the excited state of 99Tc but also by electrons
from the β− decay of 99Mo. Additionally, the radioactive molybdenum will
be produced during irradiation of a patient. In such therapy, the dose en-
hancement depends on many factors: a concentration of nanoparticles, an
activity of the radioisotope, a time of irradiation, a distribution of nanopar-
ticles in a target volume, etc. In the suggested method, a dose is delivered
even after the irradiation séance, however, due to the relatively low energy
of photons and the low activity of the radioisotopes, it does not cause a
radiological risk. We believe that suggested in this work application of 99Mo
as a dose enhancement tool is worthy of consideration but requires further
investigation.
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4. Conclusions
A long time of irradiation of the target (about several hundred hours) is
needed to obtain the saturation state due to a relatively long half-life of 99Mo
(65.9 h). The radioisotopes with shorter half-lives reach the saturation state
in a shorter irradiation time and generally, the obtained specific activities
are greater. The relatively small activities of 99Mo were obtained, because
only 16% of photons from the 20 MV X-ray beam have sufficiently high
energy to cause the 110Mo(γ, n)99Mo reaction. In order to obtain greater
activities, beams with higher energies have to be used because the mean
energy of the beam should be close to that related to the maximum of the
photonuclear cross section. Attempts to increase the induced activity of
99Mo are in progress.
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